Plus, news about Cerevance, Oncopeptides, LifeMine, Bavarian Nordic and Eagle Pharmaceuticals:
South Korean biotech’s Series B: Prazer Therapeutics nabbed a $20 million Series B from Premier Partners, K2 Investment, Johnson & Johnson’s corporate VC arm ...
↧